Table 1.
BARCODE1 pilot study screening, response rates and saliva returns.
| Site | Screened, n | Mail‐outs, n | Total responders, n (%) | Eligible, n | Returned saliva samples, n (% of eligible responders) |
|---|---|---|---|---|---|
| GP 1 | 148 | 148 | 45 (30) | 45 | 42 (93) |
| GP 2 | 350 | 326 | 78 (24) | 66 | 62 (94) |
| GP 3 | 277 | 175 | 23 (13) | 12 | 12 (100) |
| GP 4 | 267 | 232 | 46 (20) | 44 | 41 (93) |
| GP 5 | 223 | 211 | 51 (24) | 49 | 44 (90) |
| GP 6 | 390 | 200 | 93 (47) | 77 | 74 (96) |
| GP 7 | 145 | 142 | 37 (26) | 34 | 30 (88) |
| RMH* | 2 | 2 | 2 | 2 | 2 |
| Total | 1802 | 1436 | 375 (26) | 329 | 307 (93) |
GP, General Practice site.
*
Two participants recruited via Oncogenetics Research clinic in RMH.